Endpoints News

Roivant CEO, bullish on internal growth, dodges M&A chatter

These days, if you ask the CEO of Roivant if he’s open to selling another late-stage drug to a larger company, he refers you to a spoof video clip.

This report was first published by Endpoints News. To see the original version, click here

These days, if you ask the CEO of Roivant if he’s open to selling another late-stage drug to a larger company, he refers you to a spoof video clip.

It’s the scene from “Toy Story” where the alien toys are watching the arcade claw descend upon them, and Woody and Buzz Lightyear are trying to escape the machine. In the video, the aliens are labeled as biotechs ripe for a buyout, the claw is big pharma and Woody is Roivant.

您已阅读12%(513字),剩余88%(3652字)包含更多重要信息,订阅以继续探索完整内容,并享受更多专属服务。
版权声明:本文版权归Endpoints News所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。
设置字号×
最小
较小
默认
较大
最大
分享×